Business of Biotech Shorts

  1. Ep. 258, Chapter 5: Procurement Pitfalls in Funding and Sourcing with Tom Wells 7/30/2025

    Wells emphasizes that poor procurement practices in early-stage biotech can significantly damage future fundraising efforts, as investors increasingly prioritize a company's operational efficiency and responsible use of funds. He states that a cutting-edge approach to sourcing involves a combination of "innovative innovation" and supplier diversity — moving beyond traditional RFPs to Requests for Outcome (RFOs).

  2. Ep. 258, Chapter 4: Procurement for Early Stage Biotechs with Tom Wells 7/30/2025

    Wells highlights two critical inflection points for biopharma companies: moving from pre-clinical to clinical stages, and then from clinical to commercial. The first transition demands acquiring a wide array of new resources—both scientific (CROs, lab space, reagents) and non-scientific (office space, HR services, legal counsel)—many of which are expensive, complex, and heavily regulated.

  3. Ep. 258, Chapter 3: Procurement Relationship Building with Tom Wells 7/30/2025

    Wells asserts that positioning your company as a "customer of choice" comes down to basic decency: treat suppliers with respect, understand their challenges, and focus on mutual benefit beyond mere cost. He explains that, while less sophisticated procurement prioritizes cost above all, a more effective approach in today's volatile world balances price with resilience and long-term value.

  4. Ep. 258, Chapter 2: Biotech Procurement Fundamentals with Tom Wells 7/30/2025

    Wells defines procurement as the "front end of demand flow," a strategic function that brings new ideas and suppliers into a business rather than just a back-end process. He explains that the basic principles of procurement are consistent across industries, but success in life sciences demands a deep understanding of the scientific and business objectives to truly identify and create value.

  5. Ep. 258, Chapter 1: Introduction To Tom Wells And 4C Associates 7/30/2025

    Life Science Leader Chief Editor Ben Comer introduces Tom Wells, Director of Life Sciences at 4C Associates, to discuss the critical role of procurement in biotech. Wells — who has experience at companies like Novartis, Takeda, and BMS — began his career in marketing before discovering procurement at Electrolux, where he helped reposition it as a strategic function.

  6. Ep. 257, Chapter 7: The Persistent Threat Of Infectious Disease With Thomas Levenson 7/28/2025

    The COVID-19 pandemic, despite its devastation, served as a "mild warning," Levenson states, reasoning that a disease with similar transmissibility but a higher mortality rate would be far more socially disruptive. Levenson praised the rapid scientific response to COVID-19—sequencing the genome in weeks and developing vaccines within months—as an "extraordinary triumph" of modern biology and industrial capacity.

  7. Ep. 257, Chapter 6: Research Funding, Cuts, And Lessons Learned With Thomas Levenson 7/28/2025

    Levenson states that curiosity-driven basic science often seeds unexpected, beneficial technological developments. He cautions that relying on individual philanthropists is not a sustainable solution because private funding can be sporadic. So, for science on the scale required by modern society, social-level funding is essential and should not be subject to the whims of changing political administrations.

  8. Ep. 257, Chapter 5: The Challenges Of Microbiomes And Antibiotic Resistance With Thomas Levenson 7/28/2025

    Levenson acknowledges the microbiome as a potential new frontier for germ theory, acknowledging its immense complexity since traditional germ theory focuses on individual microbes with clear cause-and-effect relationships, while the microbiome is an intricate ecosystem within our bodies. Past clinical failures in developing microbiome-targeted drugs highlight how much more there is to learn.

  9. Ep. 257, Chapter 4: Unseen Biases In Modern Science With Thomas Levenson 7/28/2025

    Levenson states that it is inherently difficult to identify current scientific and medical biases, drawing parallels to historical assumptions like miasma theory. He highlights that societal willingness dictates scientific research — for example, how political decisions in the US have shifted NIH and NSF focus from infectious diseases to chronic conditions.

  10. Ep. 257, Chapter 3: Early Germ Theory Insights From Unlikely Sources With Thomas Levenson 7/28/2025

    Several lesser-acknowledged individuals contributed significantly to understanding of germ theory, including Cotton Mather, often remembered as a Puritan "hellfire and brimstone" figure. Mather compiled an extensive, though unpublished in his lifetime, encyclopedia of medical knowledge called “The Angel of Bethesda,” and became a pioneer in smallpox inoculation, learning the practice from his enslaved servant, who had been inoculated in Africa.